NewGenIvf Group

NewGenIvf Group ROCE

The Return on Capital Employed (ROCE) of NewGenIvf Group (NIVF) as of Oct 21, 2026 is -41.28 %. In the previous year, Return on Capital Employed (ROCE) was 78.29 % — a change of -152.73% (lower).

ROCE

-41.28 %

YoY

-152.73%

Last updated:

In 2025, NewGenIvf Group's return on capital employed (ROCE) was -41.28 %, a -152.73% increase from the 78.29 % ROCE in the previous year.

The NewGenIvf Group ROCE history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

ROCE
Date
ROCE
Jan 1, 2021
-21.72 USD
Jan 1, 2022
396.00 USD
Jan 1, 2023
-16.17 USD
Jan 1, 2024
78.29 USD
Jan 1, 2025
-41.28 USD
The NewGenIvf Group ROCE history
YEARROCEYoY
-41.28 %-152.73%
78.29 %-584.21%
-16.17 %-104.08%
396.00 %-1,922.84%
-21.72 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NewGenIvf Group Stock analysis

What does NewGenIvf Group do? NewGenIvf Group Ltd provides comprehensive fertility services across Asia, including IVF, ICSI, IUI, and MRT techniques. The company operates clinics in Thailand, Cambodia, and Kyrgyzstan, offering treatments such as embryo transfer, chromosome screening, egg freezing, and sperm aspiration. Patients seeking assisted reproductive technology services, including those requiring third-party egg donation or surrogacy, are the primary customers. The firm generates revenue through direct patient fees for these specialized fertility treatments and related services across its Asian clinics. The company's service portfolio includes Mitochondrial Replacement Therapy In Reproductive, Intrauterine Insemination (IUI), In Vitro Fertilization (IVF), Intracytoplasmic Sperm Injection (ICSI), semen analysis, and sperm extraction procedures. These services are delivered through clinics in Thailand, Cambodia, and Kyrgyzstan, targeting individuals and couples facing infertility challenges. Revenue is derived from the full range of fertility treatments provided at these locations. NewGenIvf Group Ltd's offerings encompass full-spectrum infertility care, including egg and sperm donation programs and surrogacy services within compliant jurisdictions. The clinics serve patients requiring advanced reproductive technologies, with MRT being a specialized service involving third-party egg contribution. The business model relies on direct patient payments for all treatment packages and ancillary services provided at its Asian locations. NewGenIvf Group is one of the most popular companies on Eulerpool.

ROCE Details

Unraveling NewGenIvf Group's Return on Capital Employed (ROCE)

NewGenIvf Group's Return on Capital Employed (ROCE) is a financial metric that measures the company's profitability and efficiency with respect to the capital employed. It is calculated by dividing earnings before interest and tax (EBIT) by the employed capital. A higher ROCE indicates that the company is effectively utilizing its capital to generate profits.

Year-to-Year Comparison

Analyzing NewGenIvf Group's ROCE annually provides valuable insights into its efficiency in using its capital to generate profits. An increasing ROCE indicates improved profitability and operational efficiency, whereas a decrease might signal potential issues in capital utilization or business operations.

Impact on Investments

NewGenIvf Group's ROCE is a critical factor for investors and analysts for evaluating the company’s efficiency and profitability. A higher ROCE can make the company an attractive investment, as it often signifies that the firm is generating adequate profits from its employed capital.

Interpreting ROCE Fluctuations

Changes in NewGenIvf Group’s ROCE are attributed to variations in EBIT or the capital employed. These fluctuations offer insights into the company’s operational efficiency, financial performance, and strategic financial management, assisting investors in making informed investment decisions.

Frequently Asked Questions about NewGenIvf Group stock

Return on Capital Employed (ROCE) of NewGenIvf Group is -41.28 % in 2025.

Return on Capital Employed (ROCE) of NewGenIvf Group changed from 78.29 % to -41.28 %, representing a -152.73% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Return on Capital Employed (ROCE) NewGenIvf Group since 2006 – with annual values, charts, and detailed analysis.

ROCE is a profitability measure and stands for Return on Capital Employed or the return on invested capital. The measure shows the ratio of operating profit to the interest-bearing capital employed. The higher the return on capital employed, the more profitable a company operates and the higher the important free cash flow. The free cash flow refers to the portion of profits that is not needed for expanding the company at the end of a period, but is available to shareholders.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Return on Capital Employed (ROCE)'s NewGenIvf Group with sector peers and the industry average to assess whether it is attractive.

To evaluate Return on Capital Employed (ROCE)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Return on Capital Employed (ROCE).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Profitability — NewGenIvf Group

All Key Metrics — NewGenIvf Group